CONCLUSIONS: PROs are significantly lower in patients with NASH with advanced fibrosis who participated inthe STELLAR clinical trials. Treatment of patients with NASH should focus on improving notonly clinical outcomes but also quantifiable symptom burden and health-related quality of life